Copyright ©The Author(s) 2021.
World J Virol. Mar 25, 2021; 10(2): 62-68
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.62
Table 1 Clinical differences between influenza and coronavirus disease 2019
Clinical differences
Signs and symptomsInfluenza: Mild to severe illness, including common signs and symptoms. COVID-19: More serious illnesses in some people. Change or loss of taste or smell may be included
Incubation periodFlu: 1-4 d after infection. COVID-19: 5 d, but symptoms can appear as early as 2 d or as late as 14 d after infection
Duration of the symptomsFlu: 3-7 d. COVID-19: 2-3 wk
Asymptomatic patientsFlu: 10%. COVID-19: A few 60%
Table 2 Combination/bundle of the candidate drugs for coronavirus disease 2019 treatment based on the pathophysiological characteristics
Pathophysiological characteristics
Antiviral drugs
Remdesivir for moderate to very severe patients
Favipiravir for mild to severe patients
Corticosteroids for moderarte to very severe patients
Tocilizumab for hospitalized COVID-19 patients
Jak/Stat signaling inhibitors for hospitalized COVID-19 patients
Anticoaglnat drugs
Table 3 Comparison of the novel coronavirus disease 2019 vaccines in clinical trials
Clinical trials
Pfizer vaccine (Name: BNT 162b2)
Type: mRNA
Age: ≥ 16 years old
Dose: 30 μg (0.3 mL) twice (21 d interval)
Efficiency (95%CI): 95.0% (90.3-97.6)
Moderna vaccine (Name: mRNA-1273)
Type: mRNA
Age: ≥ 18 years old
Dose: 100 μg (0.5 mL) twice (28 d interval)
Efficiency (95%CI): 94.5% (86.5-97.8)
AstraZeneca vaccine (Name: ChAdOx1)
Type: Virus vector
Age: ≥ 18 years old
Dose: Low doss: 2.2 × 1010 virus particle andStandard dose: 5 × 1010 virus particle, twice (28 d interval)
Efficiency (95%CI): 90.0% (67.4-97.0)